-
Finance
CSPC Pharmaceutical Group (01093.HK): Receives US$30 Million Upfront Payment Under siRNA Collaboration Agreement with AstraZeneca
-
Finance
New City Development Group (00456.HK): Appointment of Li Yang as Co-Chief Executive Officer
-
Finance
ORIENTAL EXPL (00430.HK): Expects Interim Profit to Fall to Approximately HK$ 3,000,000-3,200,000 on Lower Rental Income
-
Finance
V.S. INT'L (01002.HK): Expects Interim Profit of USD 3,000,000-4,000,000, Markedly Up from the Same Period Last Year
-
Finance
HENGRUI PHARMA (01276.HK): SHR-7590 Injection Receives Drug Clinical Trial Approval Notice for Ulcerative Colitis and Crohn's Disease
-
Finance
CAPINFO (01075.HK): Expects Interim Results to Swing to Loss of Approximately RMB 30-50 Million
-
Finance
CH TIANBAO GP (01427.HK): Expects Interim Net Loss to Widen to RMB 60-70 Million on Reduced Revenue
-
Finance
MULTIFIELD INTL (00898.HK): Expects Interim Profit to Fall to Approximately HK$ 100-120 Million on Lower Fair Value Gains on Financial Assets
-
Finance
HENGRUI PHARMA (01276.HK): HRS-4729 Injection Approved for Phase II Clinical Trial in Type 2 Diabetes
-
Finance
CHUANGLIAN HOLD (02371.HK): Zhang Jie Resigns as Executive Director, Gao Rui Appointed to Replace Him, Effective 12 August 2026
-
-
Scan QR Code
Download App
